Targeting surface nucleolin with multivalent HB-19 and related Nucant pseudopeptides results in distinct inhibitory mechanisms depending on the malignant tumor cell type

Overview of attention for article published in BMC Cancer, August 2011

Altmetric Badge

About this Attention Score

Average Attention Score compared to outputs of the same age
Good Attention Score compared to outputs of the same age and source (66th percentile)

Mentioned by

patent: 2 patents

Citations

dimensions_citation: 52 Dimensions

Readers on

mendeley: 72 Mendeley
citeulike: 1 CiteULike

Summary Patents Dimensions citations

So far, Altmetric has seen 2 patents that reference this research output.

COMBINATION THERAPY OF NUCANT AND mTOR INHIBITORS FOR TREATING CANCER

Application WO-2022223544-A1

World Intellectual Property Organisation (WIPO)

DYNORPHIN A ANALOGS WITH BRADYKININ RECEPTORS SPECIFICITY FOR MODULATION OF NEUROPATHIC…

Application WO-2014190313-A3

World Intellectual Property Organisation (WIPO)

This page shows the most recent patents that mention this research output.

Click here to find out how to access more activity.